Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients

Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients

Abstract Background Sirukumab, a high-affinity human monoclonal antibody that selectively binds to interleukin-6, has demonstrated efficacy in the treatment of rheumatoid arthritis (RA) in global phase 1 and phase 2 studies. The present study evaluated the safety and efficacy of sirukumab, as monoth...

Full description

Bibliographic Details
Main Authors: Tsutomu Takeuchi, Hisashi Yamanaka, Masayoshi Harigai, Ryo Tamamura, Yuichi Kato, Yoshifumi Ukyo, Toshikazu Nakano, Benjamin Hsu, Yoshiya Tanaka
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Arthritis Research & Therapy
Subjects:
Biologicals
Disease-modifying anti-rheumatic drugs
Interleukin-6
Rheumatoid arthritis
Sirukumab
Online Access:http://link.springer.com/article/10.1186/s13075-018-1536-9

Internet

http://link.springer.com/article/10.1186/s13075-018-1536-9

Similar Items